Core Insights - Scienture Holdings, Inc. has successfully added Arbli (losartan potassium) Oral Suspension to key national payors' formularies, expanding access to over 100 million covered lives in the U.S. [1][2][3] Product Overview - Arbli is the first FDA-approved ready-to-use oral suspension formulation of losartan potassium, providing a safe and convenient alternative to solid dosage forms [2][4]. - The U.S. losartan market is valued at approximately $256 million annually, with over 71 million prescriptions written each year, indicating a significant commercial opportunity for Scienture [2][4]. - Arbli is designed for patients over six years old and is indicated for the treatment of hypertension, reducing the risk of stroke, and treating diabetic nephropathy in certain patients with type 2 diabetes [4][7]. Market Impact - The inclusion of Arbli in major national formularies reflects the confidence health plans have in Scienture's products and enhances patient access to affordable treatment options [3][4]. - The product's unique formulation does not require compounding, has a reduced dosing volume, and offers a long shelf life at room temperature, addressing common issues associated with traditional losartan prescriptions [4][5]. Company Strategy - Scienture's leadership emphasizes the commitment to sustainable growth and improving public health outcomes through expanded access to its product portfolio [3][4]. - The company aims to make its specialty products available to millions more patients across the country, indicating a broader strategy for market penetration [3].
SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans